| __timestamp | ImmunityBio, Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4326000 | 9335772 |
| Thursday, January 1, 2015 | 226206000 | 12390000 |
| Friday, January 1, 2016 | 94391000 | 25602000 |
| Sunday, January 1, 2017 | 53821000 | 21262000 |
| Monday, January 1, 2018 | 35463000 | 28430000 |
| Tuesday, January 1, 2019 | 46456000 | 40849000 |
| Wednesday, January 1, 2020 | 71318000 | 60210000 |
| Friday, January 1, 2021 | 135256000 | 83664000 |
| Saturday, January 1, 2022 | 102708000 | 104097000 |
| Sunday, January 1, 2023 | 129620000 | 106916000 |
Unlocking the unknown
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. ImmunityBio, Inc. and Iovance Biotherapeutics, Inc. have been navigating this challenge since 2014. Over the past decade, ImmunityBio has seen a significant fluctuation in its SG&A costs, peaking in 2015 with a staggering 2,262% increase from the previous year. Meanwhile, Iovance Biotherapeutics has maintained a more consistent trajectory, with a notable 14% increase in 2023 compared to 2022.
Despite ImmunityBio's higher average SG&A expenses, Iovance's steady growth suggests a more controlled approach to cost management. As both companies continue to innovate in the biotech space, their ability to optimize these expenses will be pivotal in sustaining their competitive edge. Investors and industry watchers should keep a close eye on these trends as they unfold in the coming years.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and ImmunityBio, Inc.
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs Iovance Biotherapeutics, Inc.
Neurocrine Biosciences, Inc. and Iovance Biotherapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and ImmunityBio, Inc.
BioMarin Pharmaceutical Inc. and Iovance Biotherapeutics, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Catalent, Inc. vs ImmunityBio, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Arrowhead Pharmaceuticals, Inc. or Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: ImmunityBio, Inc. vs MannKind Corporation Trends and Insights
SG&A Efficiency Analysis: Comparing ImmunityBio, Inc. and Taro Pharmaceutical Industries Ltd.
Breaking Down SG&A Expenses: ImmunityBio, Inc. vs Travere Therapeutics, Inc.
Mesoblast Limited or Iovance Biotherapeutics, Inc.: Who Manages SG&A Costs Better?